These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8668979)

  • 1. [Adverse effects due to unstable blood products].
    Hauser SP; Nydegger UE
    Schweiz Med Wochenschr; 1996 Apr; 126(15):637-45. PubMed ID: 8668979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risks associated with blood and blood product transfusion.
    Higgins C
    Br J Nurs; 2000 Dec 8-2001 Jan 10; 9(22):2281-90. PubMed ID: 12271194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed hemolytic transfusion reaction due to anti-Fyb caused by a primary immune response: a case study and a review of the literature.
    Kim HH; Park TS; Oh SH; Chang CL; Lee EY; Son HC
    Immunohematology; 2004; 20(3):184-6. PubMed ID: 15373650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Blood transfusion complications due to Duffy factor (Fya) incompatibility].
    Umnova MA; Skachilova NN; Piskunova TM; Molchanova NP; Shakhsuvarov VD
    Probl Gematol Pereliv Krovi; 1982 Dec; 27(12):11-5. PubMed ID: 7156083
    [No Abstract]   [Full Text] [Related]  

  • 5. The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice.
    Campbell-Lee SA; Liu J; Velliquette RW; Halverson GR; Shirey RS; Chaudhuri A; Reid ME; Ness PM; Baldwin WM
    Transfusion; 2006 Oct; 46(10):1682-8. PubMed ID: 17002623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of risks related to blood transfusions in industrialized countries].
    Salamon R; Lawson-Ayayi S; Salmi LR
    Rev Epidemiol Sante Publique; 1994; 42(5):408-15. PubMed ID: 7973000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transfusion dilemma--weighing the known and newly proposed risks of blood transfusions against the uncertain benefits.
    Refaai MA; Blumberg N
    Best Pract Res Clin Anaesthesiol; 2013 Mar; 27(1):17-35. PubMed ID: 23590913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: immune anti-D stimulated by transfusion of fresh frozen plasma.
    Connolly M; Erber WN; Grey DE
    Immunohematology; 2005; 21(4):149-51. PubMed ID: 16472015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk of immunization to blood cells and diagnostic and therapeutic implications].
    Kiefel V
    Beitr Infusionsther; 1993; 31():44-51. PubMed ID: 7693263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transfusion management of patients with alloanti-Gerbich antibodies: case report].
    Jovanović R; Bujandrić N; Lisulov S; Bogdanović S
    Srp Arh Celok Lek; 2011; 139(7-8):518-22. PubMed ID: 21980665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Case of post-transfusion shock caused by alloimmunization with antigens E and Duffy (Fya)].
    Grzywak-Kołodziejczyk T; Skotnicka B; Kołodziejczyk M; Lawniczak K; Samek E
    Wiad Lek; 1981 May; 34(9):761-6. PubMed ID: 6792791
    [No Abstract]   [Full Text] [Related]  

  • 12. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.
    Berséus O; Boman K; Nessen SC; Westerberg LA
    Transfusion; 2013 Jan; 53 Suppl 1():114S-123S. PubMed ID: 23301963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood product transfusions and reactions.
    Osterman JL; Arora S
    Emerg Med Clin North Am; 2014 Aug; 32(3):727-38. PubMed ID: 25060259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fatal delayed hemolytic transfusion reaction in a postoperative case of traumatic aortic rupture].
    Shigeta O; Akishima S; Watanabe Y; Hasegawa N; Unno H; Sakakibara Y; Ijima H; Tsutsui T; Okamura K; Mitsui T
    Kyobu Geka; 1990 Jun; 43(6):498-501. PubMed ID: 2117089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood.
    Yamane K; Yagihashi A; Sasaki M; Kuwashima K; Morio A; Watanabe N
    Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):531-9. PubMed ID: 9805232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Root cause analysis of non-infectious transfusion complications and the lessons learnt.
    Karim F; Moiz B; Shamsuddin N; Naz S; Khurshid M
    Transfus Apher Sci; 2014 Feb; 50(1):111-7. PubMed ID: 24239270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Cox JV; Steane E; Cunningham G; Frenkel EP
    Arch Intern Med; 1988 Nov; 148(11):2485-9. PubMed ID: 3142382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells.
    Irani MS; Karafin MS; Ernster L
    J Clin Apher; 2017 Feb; 32(1):59-61. PubMed ID: 27112240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-infectious complications of transfusion therapy.
    Perrotta PL; Snyder EL
    Blood Rev; 2001 Jun; 15(2):69-83. PubMed ID: 11409907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.